

2025 North Campus Antibigram

Gram Positive Organisms						
Antibiogram 2025 North Campus	*Anaerobic coverage	Enterococcus faecalis	Staphylococcus epidermidis	Staphylococcus saprophyticus	Staph aureus (MSSA)	Staph aureus (MRSA)
# of isolates analyzed		176	69	34	95	85
		% Susceptible				
Ampicillin	*	99%				
Ceftaroline					100%	100%
Clindamycin	*		59%	85%	74%	65%
Daptomycin		100%			99%	100%
Erythromycin Base, Enteric	*		44%	56%	59%	9%
Gentamicin Synergy		82%				
Levofloxacin		86%				
Linezolid		98%	100%	100%	100%	100%
Nitrofurantoin		100%	100%	100%	100%	99%
Oxacillin			56%	44%	100%	0%
Penicillin G			0%	0%	0%	0%
Streptomycin Synergy		95%				
Tetracycline/Doxycycline	*		82%	91%	87%	75%
Trimethoprim-sulfa			73%	97%	93%	78%
Vancomycin		98%	100%	100%	100%	100%

Organisms are reported when 30 or more are encountered per calendar year.

This antibiogram contains organisms isolated in 2024 and has been prepared from SCC SOFT LIS.
 Only the first isolate per patient is included in the data per CLSI guidelines.
 *Denotes activity against anaerobes. Anaerobes are not tested for susceptibility profiles at WakeMed.
 16% of North MSSA isolates are positive for Clindamycin Inducible Resistance.
 9% of North MRSA isolates are positive for Clindamycin Inducible Resistance.

Antibiograms are published annually for WakeMed Raleigh, WakeMed Cary and WakeMed North
 by the Microbiology Lab and the Antimicrobial Stewardship Program. 919-350-8075

WakeMed Health and Hospitals
 Raleigh, NC